Andrew K. Haack

FDA investigator

Appears on 12 documents from 2017 to 2023, mostly at sites in Washington. Most often cites control of microbiological contamination (21 CFR 211.113).

12
Documents on file
5.0
Observations per 483
2017
First seen
2023
Most recent

What they cite most

From 55 observations

Activity by year

2017: 2, 2018: 2, 2019: 6, 2023: 2

Where

Washington 7 · California 4 · Montana 1

Is Andrew K. Haack coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

12 documents, newest first
FirmOpen
483 AGC Biologics Inc.Feb 10, 2023 · Bothell, Washington
EIR AGC BiologicsFeb 10, 2023 · Bothell, Washington
483 Form 483 · FEI 3006624492Sep 18, 2019 · Richmond, California
483 Puget Sound Drug Corporation dba Key Pharmacy and Compounding CenterJun 13, 2019 · Federal Way, Washington
483 NeoBiotech Global CorporationMay 13, 2019 · Auburn, Washington
483 Pinnacle CompoundingApr 25, 2019 · Missoula, Montana
483 OLIVE BRANCH NATURAL BODY CARE LLCApr 2, 2019 · Seattle, Washington

About this profile

What does Andrew K. Haack inspect?

Andrew K. Haack appears on 12 documents on file covering 9 sites, mostly in Washington.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.42 and 21 CFR 211.188.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Andrew K. Haack is dated Feb 10, 2023.